Niche CDMO adds spray drying for highly potent drugs28 Mar 2018
The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.
IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.
The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.
The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.
Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.
“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”
This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.
Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”
Legacy ramps up preparations for new Russian track and trace sterilisation regulations
18 Jul 2019
Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.Read more
Combination technique improves polysaccharide characterization
17 Jul 2019
The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.Read more
Lubrizol integrates personal, home and health care divisions
16 Jul 2019
The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.Read more
Bosch finds buyers for its packaging machinery business
16 Jul 2019
CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".Read more
New state-of-the-art cleanroom boosts production of anticancer drugs
15 Jul 2019
The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.Read more
Colorcon chooses the Netherlands for new starch manufacturing plant
12 Jul 2019
The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.Read more
GSK opens new continuous manufacturing facilities in Singapore
11 Jul 2019
Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.Read more
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.Read more
Onyx Scientific makes strategic investment in commercial API licence
10 Jul 2019
Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.Read more
I Holland to share the science behind tool maintenance
9 Jul 2019
Proper maintenance - rather than replacement - of compression tooling will improve profitability.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation